

New Evidence to Improve Management of Patients with or at High Risk of ASCVD Events

Michael B. Bottorff, PharmD, *Chair*

Professor and Chair

Department of Pharmacy Practice

Manchester College of Pharmacy

Ft. Wayne, IN

Daniel E. Hilleman, PharmD

Professor of Pharmacy Practice

Director, Continuing Education

School of Pharmacy and Health Professions


Creighton University

Omaha, NE


Omega-3 Fatty Acids Reducing Risk in ASCVD

Daniel E. Hilleman, PharmD
Professor of Pharmacy Practice
Director, Continuing Education
School of Pharmacy and Health Professions
Creighton University
Omaha, NE


Omega-3 Fatty Acids



Alpha-linolenic acid (ALA, C18:3, omega-3)





Eicosapentaenoic acid (EPA, C20:5, omega-3)




Docosahexaenoic acid (DHA, C22:6, omega-3)

Triglycerides




Lipoprotein Classification




Clinical Trials of Omega-3 Fatty Acids and ASCVD Risk

Study (Year)	EPA/DHA Dose (mg/d)	EPA / DHA Source
DOIT (2010)	1150 / 800	Dietary supplement
AREDS-2 (2014)	650 / 350	Dietary supplement
SU.FOL.OM3 (2010)	400 / 200	Dietary supplement
JELIS (2007)	1800 / 0	Pure EPA Rx
Alpha Omega (2010)	226 / 150	Margarine with dietary supplement
OMEGA (2010)	460 / 380	Rx EPA/DHA
R&P (2013)	500 / 500	Rx EPA/DHA
GISSI-HF (2008)	850 / 950	Rx EPA/DHA
ORIGIN (2012)	465 / 375	Rx EPA/DHA
GISSI-P (1999)	850 / 1700	Rx EPA/DHA



ASCEND: Effect of Omega-3 FA Supplements on Serious Vascular Events


- ASCEND - largest and longest duration placebo-controlled randomized trial of OM-3 FA supplementation in diabetics
- No effect on MACE
- No effect on cancer
- No effect on total or cause-specific mortality
- No safety concerns




*1-g capsules containing either n-3 fatty acids (fatty acid group) matching placebo (olive oil) daily.
ASCEND Study Collaborative Group et al. *N Engl J Med.* 2018;379:1540-50.

The VITamin D and OmegA-3 Trial (VITAL)

- 25,871 participants (primary prevention) median F/U 5.3 yrs
- MACE not significantly different between OM-3 FA and placebo (HR 0.92; $p=0.24$)
- MI was significantly reduced - HR=0.72 (0.59–0.90)
 - Blacks and lower fish intake
- Major CVD events and total invasive cancer were not significantly reduced by OM-3 FA



REDUCE-IT: Reduction of CV Events with Icosapent Ethyl – Intervention Trial




REDUCE-IT Primary Endpoint

CV Death, MI, Stroke, Coronary Revascularization, Unstable Angina


Primary Endpoint

CV Death, MI, Stroke, Coronary Revascularization, Unstable Angina




Key Secondary Endpoint

CV Death, MI, Stroke



REDUCE-IT: Prespecified Hierarchical Testing



REDUCE-IT: Treatment Emergent Adverse Events

	Icosapent Ethyl (N=4089)	Placebo (N=4090)	P
Subjects with at least one TEAE, n (%)	3343 (81.8%)	3326 (81.3%)	0.63
Serious TEAE	1252 (30.6%)	1254 (30.7%)	0.98
TEAE leading to withdrawal of study drug	321 (7.9%)	335 (8.2%)	0.60
Serious TEAE leading to withdrawal of study drug	88 (2.2%)	88 (2.2%)	1.00
Serious TEAE leading to death	94 (2.3%)	102 (2.5%)	0.61

REDUCE-IT: Adverse Events of Interest

Serious Bleeding and AF

	Icosapent Ethyl (N=4089)	Placebo (N=4090)	P
Bleeding related disorders	111 (2.7%)	85 (2.1%)	0.06
Gastrointestinal bleeding	62 (1.5%)	47 (1.1%)	0.15
Central nervous system bleeding	14 (0.3%)	10 (0.2%)	0.42
Other bleeding	41 (1.0%)	30 (0.7%)	0.19
<ul style="list-style-type: none">• No fatal bleeding events in either group• Adjudicated hemorrhagic stroke – no significant difference between treatments (13 icosapent ethyl vs 10 placebo; P=0.55)			
Adjudicated hospitalization for atrial fibrillation/flutter	127 (3.1%)	84 (2.1%)	0.004

Limitations – REDUCE-IT

- Small proportion of patients on ezetimibe
- Concomitant PCSK9 inhibitors prohibited
- LDL-C increased in both arms – 5 mg/dL more in placebo arm
 - Most likely due to mineral oil in placebo
 - LDL-C increase unlikely to account for 25% RRR
 - Benefit of EPA vs placebo consistent with or without increased LDL-C
- Mechanism of EPA benefit cannot be established based on REDUCE-IT
 - Most likely not just TG reduction
 - Consistent benefit across TG range (135–499 mg/dL)
 - Similar benefit at 1-year comparing TG < or > 150 mg/dL
- Cost-effectiveness unknown
 - NNT of 21 – likely cost-effective

Why Did EPA-Only Omega-3 FA Reduce ASCVD Events?

- REDUCE-IT – highest dose among all OM-3 FA cardiovascular outcome trials
- Patient population – higher triglyceride levels
- Differences between EPA and DHA
 - Differ in antioxidant properties and effect on membrane lipid structure and dynamics
 - EPA associates with atherosclerotic plaque membranes
 - Reduces LDL oxidation and free radical propagation
 - Reduces signal transduction associated with inflammation
 - Improves endothelial function as well as HDL functionality
 - DHA associates with neuronal and retinal membranes promoting cholesterol rich membrane domains
 - Essential in neuronal membrane function and fluidity
 - Promote formation of cholesterol-rich extracellular crystals in cell-model membranes
 - Leads to inflammation and cellular apoptosis

Omega-3 FA Products


Prescription

- Omega-3 fatty acid ethyl esters
 - Lovaza® + generics
 - 2 g BID with food or 4 g Qday with food
- EPA ethyl esters
 - Vascepa®
 - 2 g BID with food
- Omega-3 carboxylic acids (free fatty acid form)
 - Epanova®
 - 2-4 g daily with/without food
 - Product currently not available commercially


Dietary Supplements vs Rx Fish Oil

	Prescription	Dietary Supplements
FDA Product Classification	Drug	Food
Clinical Trials Required Pre-approval	Yes	Not required FDA has to prove that a supplement is not safe to restrict use or remove from the market
FDA Pre-approval	Yes	No Proof of efficacy not required
Content and Purity	<ul style="list-style-type: none"> • Adhere to strict standards for content and purity • Digested content is pure 	<ul style="list-style-type: none"> • Contains variable amounts of OM3-FA • Most do not contain labelled content of OM3-FA • Up to 36% dietary supplement OM3-FA content is saturated fat • Oxidation • Contamination
Substitution	DHA/EPA combination products are not equivalent to EPA-only products	OM3-FA dietary supplements are not equivalent to and should not be substituted for Rx OM3-FA products

Dietary Supplement Fish Oils Are a By-product of Industrial Extraction Procedures



Dietary Supplement vs Prescription Fish Oil



1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma, Inc; 2016.
2. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.

Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA

Benjamin B. Albert¹, José G. B. Derraik¹, David Cameron-Smith¹, Paul L. Hofman¹, Sergey Tumanov², Silas G. Villas-Boas², Manohar L. Garg³ & Wayne S. Cutfield¹




Figure 1 | The actual n-3 PUFA content (EPA + DHA) contained in individual retail fish oil products in relation to the claimed content (dotted line).




Figure 2 | The content of oxidation markers in retail fish oil tested in relation to recommended international thresholds (dotted lines).

Long Chain Omega-3 Dietary Supplements: A Review of the National Library of Medicine Herbal Supplement Database

Atanaz Zargar, Pharm.D., and Matthew K. Ito, Pharm.D., FCCP, FNLA, CLS

Abstract

Background: Dietary fish oil supplements are increasingly used as an alternative to prescription-grade omega-3 fatty acids (P-OM3) for the treatment of hypertriglyceridemia. The content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in these supplement products varies widely and may result in a suboptimal response. The aim of this study was to review marketed fish oil supplements and to develop a reference for clinicians to compare products.

Methods: The National Library of Medicine Herbal Supplement Database was systematically searched using fish oil, EPA, DHA, and omega-3 fatty acid as search terms. Daily doses needed to achieve the Food and Drug Administration (FDA)-approved dose (RxDose) (3,360 mg of combined EPA and DHA) were calculated from the milligrams of EPA and DHA per serving, and suggested retail prices were used to calculate monthly cost of each product. A “usage criteria” was set to highlight products at the RxDose with a monthly cost of <\$50, daily servings <8, daily amount of vitamins A and D less than or equal to the U.S. Dietary Reference Intake upper limit defined as 10,000 and 4,000 IU, respectively, and if the product was U.S. Pharmacopeia verified.

Results: A total of 163 products were identified, and 102 nonliquid and liquid products met our entry criteria. The median amount of EPA and DHA per serving in the nonliquid products was 216 mg and 200 mg, respectively, and the median number of servings at the RxDose was 11.2 at a median monthly cost of \$63.49. The

- 102 products evaluated
- Amount of combined EPA/DHA ranged from 30 mg to 1452 mg per serving.
- The Rx Dose ranged from 3 to 112 doses per day
- Monthly cost ranged from \$15 to \$700
- Only 22% met our usage criteria

“The amount of EPA and DHA per recommended servings in these products was highly variable. Clinicians should heighten their scrutiny in terms of selection of the appropriate product.”

Knowledge, Perceptions, and Patterns of Fish Oil Use in Cardiac Patients

- Survey to determine cardiac patients' knowledge and patterns of use of fish oil-derived dietary and Rx products
- 711/1000 respondents
- Reasons for use – general health (34%), heart health (28%), arthritis (9%), lipid disorders (8%)
- 14% advised to take OM-3 FA by a HCP
- 26% knew the active ingredient
- 81% purchased through a non-pharmacy retail outlet

Omega-3 Dietary Supplements

- Pros
 - Few concentrated products are available
 - Some products relatively inexpensive
 - Available at numerous outlets
 - Data indicate most products are within accepted standards for contaminants – mercury, arsenic, dioxin, PCBs

Omega-3 Dietary Supplements

- Cons
 - Low concentrated products require many “pills” – pill burden and calories
 - Liquid products require refrigeration
 - Dosing confusion
 - “Fishy” labeling
 - “Pharmaceutical grade”
 - “Tested in FDA-approved laboratory”
 - Provide “Daily recommended intake for EPA and DHA”
 - “Krill Oil” – may contain fish oil
 - Cost often exceeds prescription co-pay
 - Variability – batch-to-batch and seasonal
 - More adverse effects
 - Some products may contain heavy metals, PCBs, and are oxidized

Fish Oil – Prescription

- Pros

- Pure
- Consistent
- Value of prescription
 - Counseling
 - Monitoring
- Greater adherence
- Adverse effects

- Cons

- Cost
 - High copay
 - Formulary coverage
- Insurance changes
- Patient perception
- Expanded indication for EPA-only product
- Guideline recommendation for EPA-only product

New Evidence to Improve Management of Patients with or at High Risk of ASCVD Events

Michael B. Bottorff, PharmD, *Chair*

Professor and Chair


Department of Pharmacy Practice

Manchester College of Pharmacy

Ft. Wayne, IN

Negative Niacin Outcome Studies (Added to Statin Therapy)

AIM-HIGH (-29% TG)




N at risk	0	1	2	3	4
Monotherapy	1696	1581	1381	910	436
Combination Therapy	1718	1606	1366	903	428

Boden WE et al. *N Engl J Med.* 2011;365:2255-67

HPS2-THRIVE (-26% TG)

Effect of ERN / LRPT on Major Vascular Events



HPS2-THRIVE Collaborative Group. *N Engl J Med.* 2014;371:203-12.

Negative* Fenofibrate CVOTs (As Statin Adjunct)

Study	CV Risk Profile	Statin Use	Daily Intervention	Median Baseline TG Level	Effect on TG Level	Primary Outcome	Primary Outcome Results
ACCORD (N=5518)	<ul style="list-style-type: none"> • T2DM • 40-79 yrs w/CVD or • 55-79 yrs w/ ≥ 2 CV risk factors 	All pts: Open-label simvastatin (mean dose: 22 mg/d)	Fenofibrate	162 mg/dL	-26%	<ul style="list-style-type: none"> • Nonfatal MI or • Stroke or • CV death (Mean f/u: 4.7 yrs)	<ul style="list-style-type: none"> • HR=0.92* (95% CI, 0.79-1.08) • P=0.32
FIELD (N=9795)	<ul style="list-style-type: none"> • T2DM • 50-75 yrs 	Added during study in 2547 pts (26%)	Fenofibrate	154 mg/dL	-30% (at 1 yr)	<ul style="list-style-type: none"> • Nonfatal MI or • CHD death Median f/u: 5 yrs	<ul style="list-style-type: none"> • HR=0.89* (95% CI, 0.75-1.05) • P=0.16

***Note that *post hoc* analysis for both studies found statistically significant benefit in the subgroup of patients with TG \geq 204 mg/dL & HDL-C \leq 34 mg/dL (Sacks FM et al. *N Engl J Med.* 2010;363:692-4).**

ACCORD Study Group et al. *N Engl J Med.* 2010;362:1563-74. Keech A et al. *Lancet.* 2005;366:1849-61.